Targeting the Hippo pathway in cancer

Area of Science:

• Cell Biology
• Molecular Biology
• Oncology

Background:

• The Hippo pathway is a conserved signaling network regulating tissue growth and cell fate.
• Aberrant Hippo signaling is linked to human diseases, especially solid cancers.
• YAP and TAZ are key transcriptional co-activators in the Hippo pathway.

Purpose of the Study:

• To explore the therapeutic potential of targeting the Hippo pathway in cancer.
• To investigate the role of YAP/TAZ-TEAD interactions in cancer progression.
• To evaluate the combination of Hippo pathway inhibitors with RAS-MAPK inhibitors.

Main Methods:

• Review of current literature on Hippo pathway signaling and cancer.
• Analysis of preclinical and clinical data on Hippo pathway-targeted therapies.
• Exploration of the functional relationship between Hippo and RAS-MAPK pathways.

Main Results:

• Hippo pathway dysregulation is a hallmark of various cancers.
• Inhibitors targeting YAP/TAZ-TEAD transcriptional activity show therapeutic promise.
• TEAD inhibitors have demonstrated efficacy in early-phase clinical trials for specific cancers.
• The Hippo pathway shares functional links with the RAS-MAPK pathway.

Conclusions:

• Targeting the Hippo pathway, particularly YAP/TAZ-TEAD interactions, represents a viable strategy for cancer treatment.
• Combination therapies involving Hippo pathway inhibitors and RAS-MAPK inhibitors hold significant potential for enhanced efficacy.
• Further research into Hippo pathway modulation could lead to novel cancer therapeutics.